About us
A team with over 300 years of dialysis experience
Triomed AB is a Swedish company dedicated to developing novel innovative therapeutic systems to improve peritoneal dialysis (PD). The Steady Concentration PD (SCPD) method offers new possibilities for PD therapy. With our new technology platform, Carry Life UF, our aim is to keep patients longer on PD by targeting the known limitations of today’s PD treatment options
Board of Directors
Mats Wahlström
Mats Wahlström has served as Chairman of the Board of Directors since 2016. He brings over 40 years of international healthcare experience, including leadership roles at Gambro and Fresenius Medical Care. He is also active on several corporate boards.
Ulf Öjerklint
Member of the Board of Directors since 2012. Ulf Öjerklint is a lawyer and senior partner at WSA law firm. He has extensive commercial law and corporate transaction experience. Ulf is active in a number of corporate boards.
Anders Helmner
Member of the Board of Directors since 2012 and a co-founder of Triomed. Anders Helmner has been involved in the development, production and distribution of medium-haul components for commercial aircraft. He has also built up the global distribution of components for long-haul commercial aircraft.
Ugo Grondelli
Member of the Board of Directors since 2012. Ugo Grondelli has a MSc in Business and Economics and an MBA from UCLA. Ugo is a founder and shareholder of Spindial Europe SA. Previous experience includes Executive Vice President of the Gambro group, Chairman of the Board of Hospal AG, Vice President of Jostra AG, and Board member of Q-Med AB. Ugo is active in a number of corporate boards.
Juan Bosch
Member of the Board of Directors since 2016. Dr Juan Bosch is a Nephrologist with extensive experience in clinical medicine, nephrology and research in artificial organs. Juan was the Chief Medical Officer of the Gambro group and Professor with Tenure at George Washington University.
Patrick Greatrex
Patrick Greatrex served as CEO of Triomed from 2016 to 2024 and has been a member of the Board of Directors since 2024. Patrick has held several CEO and senior management roles including CEO of Vivoline Medical AB and Vice President of Business Development at Gambro AB. He has Bachelor Degrees in Law and Political Science from the University of Queensland and an MBA from Lund University.
Anders Wallenås
Member of the Board of Directors since 2016 and a co-founder of Triomed. Anders Wallenås has a Master of Science in Mechanical Engineering. He has more than 30 years of experience managing industrial development projects across a range of industries.
Lars Wramner
Lars Wramner is an MD and has a Ph.D. He was a co-founder of Triomed in 2005 and entered the Board the same year. Dr. Wramner has 25 years experience as a senior consultant transplant surgeon and is an expert in dialysis access surgery.
Lars Persson
Member of the Board of Directors since 2012. Lars Persson has experience from leading positions within MedTech Venture Capital including Almi and Industrifonden. Lars is active on the Board of a number of medical technology companies.
Management
Marcello Grondelli
Chief Executive Officer
Marcello Grondelli joined Triomed AB as CEO in April 2024. He holds an MSc in Management Engineering from the Polytechnic University of Milan and has over 20 years of experience as President & CEO, growing and transforming companies in the MedTech and Healthcare sectors.
Katarina Holm
Finance and HR Manager
Katarina Holm joined Triomed in 2023. She has a Master of Business Administration degree from Lund University and a background as an auditor at Mazars AB.
Hans Bengtsson
Development Lead of Active Devices
Hans Bengtsson joined Triomed AB in 2012. He has an MSc in Mechanical Engineering from Lunds University and more than 30 years experience of leading research and developments projects.
Maria Thelin
QA/RA Manager
Maria Thelin joined Triomed in October 2024. She has 30 years of experience within life science, including roles as product quality assurance manager, quality specialist validation, and dispensing pharmacist. Her most recent employment was at Baxter, Lund.
Charlotte de Leon
Clinical and Marketing Manager
Charlotte de Leon joined Triomed in 2013 and has since then held different roles in the company within QA, RA and Clinical. She has a MSc in biomedicine and PhD in medicine from Uppsala University. She did her post-doctoral studies at Harvard Medical School and has vast experience from research within life science.
Daniel Åberg
Project Manager
Daniel Åberg joined Triomed in 2022. He has worked in the medical device industry since 2006 and holds a MSc in Engineering Physics. Daniel is also certified as a Project Management Professional and Professional Scrum Master. He has experience from project management and management roles at Atos Medical AB, Dignitana Inc, Baxter International Inc and CellaVision AB.
Vanessa Velasco
Development Lead of Disposable Products
Vanessa Velasco joined Triomed in 2022. Vanessa has worked in the Medical device industry since 2014 and has a BSc in Chemical Engineering with experience in roles as Product Risk Manager and within Design Control and Design Development.
Main Shareholders
Frankenius Equity AB
Frankenius Equity is a family office focusing mainly on investments in life science, real estate, retail, e-commerce and finance. Based in western Sweden, it engages in both domestic and international ventures, building strong partnerships by sharing our knowledge and commitment.
Visiting Adress: Lilla Brogatan 14, Borås
Postal address: Box 984, 501 10 Borås, Sweden
e.mail: hello@fraq.se
Web site: https://www.fraq.se/
HW Investment Partners, LLC / KMG Renal Investments, LLC
HW Investment Partners and KMG Renal Investments are focused on investing in healthcare companies with engaging business models, unique service concepts and disruptive technologies. Their approach is to partner with innovative companies that are driven to transform patient care and dramatically improve patient lives.
1726 Cole Blvd, Suite 320 | Lakewood, Colorado 80401, USA
e-mail: mwahlstrom@kmgcap.com
Web site: https://hwinvestpartners.com/
Quality Management System
Triomed AB is ISO 13485:2016 certified with for:
Design and Development, Production, Distribution and Service of devices for dialysis and blood treatment, for Peritoneal ultrafiltration.
Design and development, Production and Distribution of sterile Line sets for circulation of peritoneal fluid (single use).
Frequently Asked Questions
SCPD (Steady Concentration Peritoneal Dialysis) maintains an adequate dialysate glucose concentration by continuously adding small amounts of glucose, ensuring consistent ultrafiltration throughout the treatment
In conventional glucose-based peritoneal dialysis (PD), the entire volume of PD fluid is exchanged to restore an adequate glucose concentration. In contrast, with SCPD a concentrated glucose solution is used maintain the dialysate glucose concentration at an adequate level.
Yes, clinical studies have shown that the Carry Life UF treatment increased the ultrafiltration and the sodiume removal compared to a 2.27% glucose CAPD dwell.